Posted by Michael Wonder on 30 May 2024
Affimed receives fast track designation for combination therapy of AFM24 with atezolizumab for EGFR wild type non-small cell lung cancer
29 May 2024 - The FDA’s fast track designation was granted after its review of the initial efficacy data of the EGFR wild type cohort from the AFM24-102 study.
Affimed today announced that the FDA has granted fast track designation to the combination of its innate cell engager AFM24 with atezolizumab for the treatment of patients with advanced and/or metastatic non-small cell lung cancer not harbouring any activating EGFR mutations (EGFR wild type) after progression on PD-(L)1 targeted therapy and platinum-based chemotherapy.
